Global Non Alcoholic Steatohepatitis Biomarkers Market Overview
The non-alcoholic steatohepatitis biomarkers market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%.
Non-alcoholic steatohepatitis is a progressive phase of non-alcoholic fatty liver disease (NAFLD), which is caused due to the excess fat accumulation leading to inflammation and damage resulting to liver scarring. NASH biomarkers are used as diagnostic tools to measure the severity of non-alcoholic steatohepatitis and for the liver damage assessment. Emerging advancements in technology in biomarker identification for NASH is supporting in the NASH biomarker development. The non-alcoholic steatohepatitis biomarkers market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%.
Impact of COVID-19 on the market
Biopharmaceutical firms are at the leading position of the human response to the coronavirus pandemic. A significant number of foremost biotech organizations are in the middle of a race to examine the Sars-Cov-2 genome and formulate a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc., the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a significant amount of funds are being put into the R&D. With the several candidates in trial, the public and private sectors are expected to work in unison for the estimative period, until a vaccine is developed for Covid-19. This report will quantify the impact of this pandemic on the non-alcoholic steatohepatitis biomarkers market.
Global Non Alcoholic Steatohepatitis Biomarkers Market Dynamics
Increase in Prevalence of NAFLD and NASH
The prevalence rate of non-alcoholic liver diseases has grown significantly. Patients with obesity and type 2 diabetes are projected to be more susceptible to NAFLD and other liver diseases. This is projected to drive the prevalence of non-alcoholic liver diseases. High pollution levels and changes in lifestyle are expected to propel the prevalence of nonalcoholic liver diseases. This, in turn, is anticipated to propel the NASH biomarkers market over the forecast period.
Growth in the number of initiatives concerning to development of NASH drugs
The biopharmaceutical company named “GENFIT” has undertaken an initiative for NASH Education Program in 2016. It’s a public health initiative aimed to create awareness about NASH among patients. These types of programs are measured to expedite utilization of NASH therapeutics. Moreover, GENFIT started Pediatric NAFLD/NASH Program in Europe after approval of elafibranor’s Pediatric Investigation Plan by the European Medicine Agency, which is further expected to ease the drug development program in the future.
Conversely, higher cost of treatment is anticipated to limit the growth of the non-alcoholic steatohepatitis biomarkers market during the forecast period.
Global Non Alcoholic Steatohepatitis Biomarkers Market Segmentation
The non-alcoholic steatohepatitis biomarkers market is segmented based on the type, end-user, and region.
On the basis of the type, the non-alcoholic steatohepatitis biomarkers market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and others. Based on the end-user, the target market is classified into pharma & CRO industry, hospitals, diagnostic labs, and academic research institutes.
Regional Insights:
In the region, the non-alcoholic steatohepatitis biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years. Driving government initiatives, the presence of sophisticated healthcare amenities, and the growing incidence of diabetes, obesity, and fatty liver disease is supporting the growth of the target market in this region. Europe is anticipated to account the second position in the non-alcoholic steatohepatitis (NASH) biomarkers market, owing to the growing prevalence of NASH, increasing incidence of obesity and diabetics, growing research and development on liver diseases, and the existence of well-established healthcare sector. The market in the Asia-Pacific region is boosting the growth due to the existence of a large patient base, availability of skilled healthcare personnel, and growth in healthcare spending. The Middle East and Africa is projected to witness the lowest share in the market. In the African region, the market is projected to be negatively affected by factors like poor healthcare amenities, inadequate awareness about liver diseases including NASH, and a smaller amount of disposable income.
|
Attribute |
Details |
|
The base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Type - Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others By End-user – Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2029. For the purpose of this study, has segmented the non-alcoholic steatohepatitis biomarkers market report based on type, end-user, and region.
Non-alcoholic Steatohepatitis Biomarkers Market, By Type:
- Serum biomarkers
- Hepatic fibrosis biomarkers
- Apoptosis biomarkers
- Oxidative stress biomarkers
- Others
Non-alcoholic Steatohepatitis Biomarkers Market, By End-user:
- Pharma & CRO Industry
- Hospitals
- Diagnostic Labs
- Academic Research Institutes
Non-alcoholic Steatohepatitis Biomarkers Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- U.S.
- Canada
- Middle East & Africa
Global Non Alcoholic Steatohepatitis Biomarkers Market Key Players
Regional Insights:
The key players operating in the non-alcoholic steatohepatitis biomarkers market include GENFIT, Gilead, AstraZeneca, Novartis AG, GE Healthcare, EUSA Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, and Pfizer, Inc. The market is perceiving intense competition due to the growing number of liver transplantation. Rising demand for advanced diagnostic tools that help in accurate diagnosis of NASH is the key factor boosting growth. Industry players are involved in novel product development and strategic alliances, such as partnership agreements and research collaborations to aid market penetration.
Global Non Alcoholic Steatohepatitis Biomarkers Market Company Profile
- GENFIT
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Gilead
- AstraZeneca
- Novartis AG
- GE Healthcare
- EUSA Pharma
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Allergan Novo Nordisk A/S
- Pfizer, Inc.
“*” marked represents similar segmentation in other categories in the respective section
Global Non Alcoholic Steatohepatitis Biomarkers Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Types
- Key Thickness Insights
- Secondary Data
- Major Secondary Types
- Secondary Types
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for Non-alcoholic Steatohepatitis Biomarkers Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By End-user
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Type, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Serum Biomarkers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Hepatic Fibrosis Biomarkers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Apoptosis Biomarkers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Oxidative Stress Biomarkers
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Market Segmentation, By End-user, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Segment Trends
- Pharma & CRO Industry
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Hospitals
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Diagnostic Labs
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Academic Research Institutes
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2019 – 2029
- Overview
- Global Market, By Region, 2019 – 2029, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2019 – 2029
- Y-o-Y Growth Analysis (%), 2019 – 2029
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Type, 2019 – 2029
- Market Size and Forecast (US$ Mn), By End-user, 2019 – 2029
- Market Size and Forecast (US$ Mn), By Country, 2019 – 2029
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
-
- GENFIT
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Business Strategies
- Gilead
- AstraZeneca
- Novartis AG
- GE Healthcare
- EUSA Pharma
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Allergan Novo Nordisk A/S
- Pfizer, Inc.
- GENFIT
-
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global non-alcoholic steatohepatitis biomarkers market is segmented based on type, end-user, and region.
An increase in the prevalence of NAFLD and NASH is likely to drive the growth of the global non-alcoholic steatohepatitis biomarkers market over the forecast period.
North America is expected to account for the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years.
Industry players are involved in novel product development and strategic alliances, such as partnership agreements and research collaborations to aid market penetration.• For instance, in November 2019, Novartis announced positive interim results from the final part of its phase IIb FLIGHT-FXR adaptive design study, assessing the safety, tolerability, and efficacy of tropifexor in patients with biopsy-confirmed stage 2-3 fibrotic non-alcoholic steatohepatitis (NASH).